Among the kidney stone diseases, cystinuria (OMIM
220100
) is unique as it is exclusively caused by genomic alterations. Cystinuria is associated with mutations in the
SLC3A1
and the
SLC7A9
genes encoding the subunits rBAT and b
0,+
AT of the renal b
0,+
transporter. Mutations in
SLC3A1
are usually inherited autosomal recessively, but
SLC7A9
mutations result in a broad clinical variability. The detection rate for mutations is influenced by the ethnic origin of the patient and by the functional significance of the variant. As a result, mutations cannot be detected in 100% of alleles, but it reaches approximately 85%. In case of
SLC3A1
, large rearrangements in 2p21 cause cystinuria and severe hypotonia (hypotonia–cystinuria syndrome – HCS). Meanwhile, a large number of mutations in both genes have been reported, several of these variants were functionally analysed. Thereby, the aetiology of the disease as well as the physiological mechanisms of the renal trafficking of cystine could be deciphered.
Key Concepts:
Cystinuria is characterised by the defect transport of cystine, resulting in cystine stone formation.
With
SLC3A1
and
SLC7A9,
two disease causing genes have been identified.
SLC3A1
and
SLC7A9
encode the two subunits of the amino acid transporter b
0,+
.
Mutations in
SLC3A1
are predominantly associated with an autosomal recessive inheritance, whereas
SLC7A9
mutations show an autosomal dominant inheritance with an incomplete penetrance.
Homozygosity for large genomic deletions affecting both the
SLC3A1
and the
PREPL
gene in 2p21 cause the hypotonia–cystinuria syndrome.